Current status and future prospects of the strategy of combining CAR‑T with PD‑1 blockade for antitumor therapy (Review)
Jǐnjīng Xǔ(Nanjing Medical University), Junnian Zheng(Xuzhou Medical College), Qing Zhang(South China University of Technology), Hong Yin(Soochow University), Kang Tian(Xuzhou Medical College), Haiyu Wang(Leiden University Medical Center)
Cited by 18
Related Papers
Decorin is a pivotal effector in the extracellular matrix and tumour microenvironment
|Oncotarget|2018|217
DNA damage response – A double-edged sword in cancer prevention and cancer therapy
|Cancer Letters|2014|189
Apigenin suppresses PD-L1 expression in melanoma and host dendritic cells to elicit synergistic therapeutic effects
|Journal of Experimental & Clinical Cancer Research|2018|176
Combination Therapy with EpCAM-CAR-NK-92 Cells and Regorafenib against Human Colorectal Cancer Models
|Journal of Immunology Research|2018|152
HAb18G/CD147 Functions in Invasion and Metastasis of Hepatocellular Carcinoma
|Molecular Cancer Research|2007|148